Doctors recently conducted a large study to see if adding a high amount of vitamin D3 could help people with advanced colorectal cancer. This type of cancer has spread to other parts of the body. The study looked at patients who had not received prior treatment for their condition. They were divided into two groups to see how different vitamin levels affected their health.
The first group received standard chemotherapy and a common targeted drug called bevacizumab. Along with these medicines, they were given a large daily dose of vitamin D3. The second group received the exact same chemotherapy and targeted drug but only received a standard, lower dose of vitamin D. The goal was to see if the extra vitamin helped slow down the growth of the cancer.
After following the patients for about 20 months, the researchers looked at how long the cancer stayed stable. Patients who took the higher dose of vitamin D3 lived with stable cancer for about 11.8 months, while those on the lower dose lived with stable cancer for about 10.3 months. While the higher dose group had a slightly longer time, the difference was not large enough to be considered a major medical change.
Other results, such as the overall survival time and the rate at which tumors shrank, were also very similar between both groups. The researchers also checked for safety. They found that patients in both groups experienced similar side effects, such as high blood pressure or low white blood cell counts. There were no special risks found specifically from taking the higher amount of vitamin D3.
In conclusion, adding a high dose of vitamin D3 to the current standard treatment did not significantly change the outcome for patients with this type of cancer. While vitamin D is important for general health, this specific study suggests it does not act as a primary way to stop the progression of advanced colorectal cancer when added to standard chemotherapy.
